1. Disease Progression/Clinical Outcome Model for Castration‐Resistant Prostate Cancer in Patients Treated With Eribulin. (30th June 2015) Authors: van Hasselt, JGC; Gupta, A; Hussein, Z; Beijnen, JH; Schellens, JHM; Huitema, ADR Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 4:Number 7(2015:Jul.) Page Start: 386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration‐Resistant Prostate Cancer Treatment With Eribulin. (30th June 2015) Authors: van Hasselt, JGC; Gupta, A; Hussein, Z; Beijnen, JH; Schellens, JHM; Huitema, ADR Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 4:Number 7(2015:Jul.) Page Start: 374 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗